The approval will enable ViiV Healthcare to use the complete regimen as a replacement for the current antiretroviral (ARV) regimen in adults who are virologically suppressed on a The post ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato appeared first on Pharmaceutical Business review. … [Read more...]
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
There are no HER3 directed therapies approved for the treatment of NSCLC or any cancer. The frequency of HER3 overexpression in EGFR-mutated NSCLC has been reported to be The post Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC appeared first on Pharmaceutical Business review. … [Read more...]
Most Postmarketing Requirements, Commitments Were on Schedule in 2019, FDA Says
Drugmakers successfully completed a majority of postmarketing requirements and commitments in fiscal 2019, the FDA said it its latest annual report. … [Read more...]
J&J announces agreement with US govt for 100 million doses of investigational Covid-19 vaccine
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, in The post J&J announces agreement with US govt for 100 million doses of investigational Covid-19 vaccine appeared first on Pharmaceutical Business review. … [Read more...]
LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer
The results were reviewed by an independent Data Monitoring Committee (DMC) at a planned interim analysis. The safety profile for lorlatinib and crizotinib were consistent with what has The post LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer appeared first on Pharmaceutical Business review. … [Read more...]